LUNG RFA FOR EARLY-STAGE NSCLC
AND PULMONARY METASTASES

Lung RFA serves fundamentally different patient populations — inoperable early lung cancer and oligometastatic pulmonary disease. The clinical goals, eligibility criteria, and expected outcomes differ substantially.

“For an elderly patient with stage I NSCLC and COPD too severe for lobectomy — there is no surgery, no radiation with curative dose, no approved drug option. Lung RFA is not a second-best option; it is sometimes the only option that offers any chance of local disease control.”

• Role 1: Curative Intent for Inoperable Stage I NSCLC

  Approximately 20–25% of patients with stage I NSCLC (T1–T2, N0, M0) are medically inoperable — usually due to severe COPD (FEV1 <40% predicted), cardiovascular disease, or other comorbidities that make lobectomy unacceptably risky. For these patients, CT-guided RFA offers curative-intent local treatment. Lung ablation and SBRT are the two main non-surgical options; ablation has the advantage of no radiation dose and repeatability.

• Role 2: Oligometastatic Pulmonary Disease

  Patients with limited pulmonary metastases (typically 1–5 lesions) from colorectal cancer, sarcoma, renal cell carcinoma, or other primaries — where systemic therapy has achieved disease control but lung lesions persist or progress. Lung RFA ablates individual metastases while systemic therapy continues, potentially extending progression-free and overall survival in selected oligometastatic patients.

Lung ablation differs from liver or kidney RFA in important ways — the low electrical conductivity of aerated lung tissue affects heat generation, and the lung's movement with respiration adds procedural complexity.

• Low Lung Conductivity: A Technical Challenge

  Aerated lung tissue is a poor electrical conductor — the air in the lung parenchyma limits current flow. This makes RFA less efficient in lung than in solid liver or kidney tissue. More energy is required and ablation times are longer. MWA has largely overcome this limitation (microwaves propagate through air-containing tissue better than electrical current), which is why many centres now prefer MWA for lung tumours. RFA remains widely used but is being superseded for some lung applications.

• Respiratory Motion Management

  The lung moves with every breath, typically 5–25 mm depending on tumour location. For CT-guided electrode placement, patients are coached to hold their breath at the same phase (typically end-expiration) for each CT acquisition. Some centres use cone-beam CT fluoroscopy for real-time needle guidance. Accurate electrode placement is critical — 3–5 mm errors change whether the tumour margin is adequate.

• Pneumothorax: The Characteristic Complication

  The needle passes through the chest wall and pleural space to reach the tumour, inevitably creating a small pleural injury. Air can enter the pleural space (pneumothorax). This occurs in 30–50% of lung RFA procedures. Most are small and asymptomatic, resolving spontaneously. Only 10–20% require chest tube drainage. All lung RFA centres have established pneumothorax management protocols (see dedicated page).

• Margins Are Harder to Confirm

  In liver, the ablation zone is clearly visible as a low-density area on CT immediately after ablation. In lung, the ablation zone is partly obscured by haemorrhage and ground-glass opacity around the electrode track. A reactive halo of opacification surrounds the ablation zone for 4–6 weeks post-procedure. Definitive confirmation of complete ablation requires follow-up CT at 6–8 weeks showing a shrinking non-enhancing zone.

Published efficacy data from major lung RFA series for NSCLC and pulmonary metastases.

For inoperable stage I NSCLC, SBRT (stereotactic body radiotherapy) and lung ablation (RFA or MWA) are the two main curative-intent alternatives to surgery. Understanding their relationship is essential for treatment planning.

Related lung cancer and ablation topics.

Frequently Asked Questions

Common questions about lung RFA.